Form 4 for STLN Starling Oncology, Inc.
Accepted 2025-12-16 00:00:00 ET · period of report 2025-12-15 · accession 0001079973-25-001861 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-16 | 2025-12-15 | STLN | Hively Brad | Dir | S - Sale | $3.77 | -13.3K | 683.7K | -2% | -$50.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-15 | S | D | 13,333 | $3.77 | 683,721 | D | — | — | (F2) Price of $3.771921 was the volume weighted average selling price of all sales by the reporting person on December 15, 2025 within a one-dollar range. Actual prices ranged from $3.770 to $3.785. The reporting person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price. |